J&J Psoriasis Pill In A Tier Of Its Own After Phase III Win

 
• By Kevin Grogan

The US healthcare giant says that icotrokinra could provide an “industry-leading combination of significant skin clearance with demonstrated tolerability in a once-daily pill" after succeeding in late-stage trials.

Leadership concept, One leader red sphere leads other boxes
Ingrezza sales already outpace Austedo • Source: Shutterstock

More from Clinical Trials

More from Immunological